Literature DB >> 21559861

Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction.

Kazumasa Fujitani1, Manami Yamada, Motohiro Hirao, Yukinori Kurokawa, Toshimasa Tsujinaka.   

Abstract

BACKGROUND: Decision-making for surgical palliation remains one of the most challenging clinical scenarios. We investigated the optimal indications for surgical palliation in advanced gastric cancer (AGC) patients presenting with gastrointestinal (GI) obstruction.
METHODS: A retrospective analysis was performed on 53 consecutive patients who underwent surgical palliation for GI obstruction caused by AGC between 2000 and 2007 at Osaka National Hospital. The clinical course of each patient was followed until death. Postoperative improvement of oral intake, achievement of hospital discharge, and implementation of chemotherapy in each patient were documented and used as a triad to assess the quality of life (QOL). Prognostic factors for overall survival were investigated by univariate and multivariate analyses. In addition, postoperative morbidity and mortality rates were recorded.
RESULTS: Of the entire patient cohort, 64% demonstrated a QOL improvement by having achieved the triad. Performance status (PS) of 1 or less was the only significant predictive factor for QOL improvement. The median survival time (MST) of the whole patient cohort following surgical palliation was 161 days, while the MSTs of patients fulfilling the triad and of those failing to achieve the triad were 253 and 60 days, respectively, with a significant difference between them (P < 0.0001). PS of 1 or less (hazard ratio 0.265, P = 0.0008) and recurrent disease (hazard ratio 0.394, P = 0.043) were identified as significant independent prognostic factors for longer survival on multivariate analysis. Overall morbidity and 30-day postoperative mortality rates were 24.5% (13 patients) and 7.5% (4 patients) respectively.
CONCLUSIONS: In AGC patients presenting with GI obstruction, surgical palliation was beneficial in patients with PS of 0-1 and those with recurrent disease, in terms of improved QOL and prolonged survival, with acceptable operative morbidity and mortality rates.

Entities:  

Mesh:

Year:  2011        PMID: 21559861     DOI: 10.1007/s10120-011-0053-1

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  22 in total

Review 1.  Decision making on surgical palliation based on patient outcome data.

Authors:  T J Miner; D P Jaques; H Tavaf-Motamen; C D Shriver
Journal:  Am J Surg       Date:  1999-02       Impact factor: 2.565

2.  Indications and use of palliative surgery-results of Society of Surgical Oncology survey.

Authors:  Laurence E McCahill; Robert Krouse; David Chu; Gloria Juarez; Gwen C Uman; Betty Ferrell; Lawrence D Wagman
Journal:  Ann Surg Oncol       Date:  2002 Jan-Feb       Impact factor: 5.344

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study.

Authors:  N A Christakis; E B Lamont
Journal:  BMJ       Date:  2000-02-19

Review 5.  Chemotherapy for metastatic gastric cancer: past, present, and future.

Authors:  Atsushi Ohtsu
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

6.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  Chemotherapy use and associated factors among cancer patients near the end of life.

Authors:  Young Ho Yun; Miyoung Kwak; Sang Min Park; Samyong Kim; Jong Soo Choi; Ho-Yeong Lim; Chang Geol Lee; Youn Seon Choi; Young Seon Hong; Si-Young Kim; Dae Seog Heo
Journal:  Oncology       Date:  2007-12-20       Impact factor: 2.935

8.  Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors.

Authors:  Anne-Claire Barbot; Pascale Mussault; Pierre Ingrand; Jean-Marc Tourani
Journal:  J Clin Oncol       Date:  2008-05-20       Impact factor: 44.544

9.  The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy.

Authors:  Davide Tassinari; Luigi Montanari; Marco Maltoni; Michela Ballardini; Alessandra Piancastelli; Marco Musi; Giampiero Porzio; Vincenzo Minotti; Augusto Caraceni; Barbara Poggi; Anna Stella; Federica Aielli; Emanuela Scarpi
Journal:  Support Care Cancer       Date:  2007-07-13       Impact factor: 3.603

10.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  4 in total

1.  Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.

Authors:  Yu Cheng; Jin Zhou; Honglun Li
Journal:  Clin Transl Sci       Date:  2015-02-14       Impact factor: 4.689

2.  Decreased expression of eukaryotic initiation factor 3f is an adverse prognostic factor for stage I-III gastric cancer.

Authors:  Guanghua Li; Na Wang; Chuanjin Sun; Bo Li
Journal:  World J Surg Oncol       Date:  2014-03-28       Impact factor: 2.754

3.  Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis.

Authors:  Mi-Rae Kim; A-Sol Kim; Hye-In Choi; Jae-Hun Jung; Ji Yeon Park; Hae-Jin Ko
Journal:  PLoS One       Date:  2020-07-27       Impact factor: 3.240

4.  Self-expandable metal stent of esophagogastric junction versus pyloric area obstruction in advanced gastric cancer patients: Retrospective, comparative, single-center study.

Authors:  Deok Yeong Kim; Hee Seok Moon; In Sun Kwon; Jae Ho Park; Ju Seok Kim; Sun Hyung Kang; Eaum Seok Lee; Seok Hyun Kim; Byung Seok Lee; Jae Kyu Sung; Hyun Yong Jeong
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.